DANIEL D'ANDREA: Open Payments
NPI 1992763866 · HOLMDEL, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,322 in 62 payments from 10 companies in 2025. Trend: 2023 $961 · 2024 $874 · 2025 $1,322
Food & beverage: $1,249Education: $73
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 14 | $393 |
| Lundbeck LLC | 14 | $236 |
| Neurocrine BioSciences, Inc. | 10 | $187 |
| Otsuka America Pharmaceutical, Inc. | 3 | $165 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $107 |
| Bausch Health US, LLC | 6 | $98 |
| Axsome Therapeutics, Inc. | 3 | $58 |
| ABBVIE INC. | 3 | $48 |
| Eisai Inc. | 1 | $15 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14 |
Products named: REXULTI, AUSTEDO XR, INGREZZA, TRINTELLIX, WELLBUTRIN, Auvelity, VRAYLAR, APLENZIN.
Industry payments across NJ — which companies pay providers there.
